JY028 Single Vitreous Injection in a Phase 1 Clinical Trial in nAMD Patients
Status:
Unknown status
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
Phase I clinical trial on safety, tolerance, pharmacokinetics (PK) and pharmacodynamics of
recombinant human anti-VEGF monoclonal antibody injection in patients with neovascular (wet)
age-related macular degeneration